Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Noam E. Kopmar(University of Washington), Katherine C. Sutherland(Stanford University), Joshua Sasine(Cedars-Sinai Medical Center), Christian Gordillo, Catherine J. Lee(University of Utah), Kristen M. O’Dwyer(University of Rochester Medical Center), Vivian Michelle Irizarry Gatell, María Silvina Odstrcil Bobillo(University of Utah), Paul Shaughnessy(CHRISTUS Transplant Institute), Navneet S. Majhail(Sarah Cannon), Divya Koura(University of California San Diego), Aravind Ramakrishnan(Fred Hutch Cancer Center), Matthew P. Connor(Hospital of the University of Pennsylvania), Roshini Pradeep, Sumithira Vasu(The Ohio State University), Marc Schwartz, Jacob Boccucci(Augusta University Health), Luke Mountjoy(Colorado Blood Cancer Institute), Caspian Oliai(APLA Health), Evandro D. Bezerra(Cleveland Clinic), Tamer Othman(City Of Hope National Medical Center), Ibrahim Aldoss(City of Hope), Olalekan O. Oluwole(Vanderbilt University), Kevin Tang, Gregory W. Roloff(University of Chicago), Evan C. Chen(Dana-Farber Cancer Institute), Rasmus T. Hoeg(University of California, Davis), John Mathews, Ibrahim N. Muhsen, Muthu Sendhil Kumaran(Post Graduate Institute of Medical Education and Research), Vamsi Kota(Augusta University), Caitlin Guzowski(Northside Hospital), Talal Hilal(WinnMed), Chenyu Lin(Duke University), Kaitlyn C. Dykes(University of California San Diego), Abdullah Ladha(University of Southern California), Ran Reshef(Abramson Cancer Center), Yannis K. Valtis(Brigham and Women's Hospital), Ted Gooley(Fred Hutch Cancer Center), Noelle V. Frey(Hospital of the University of Pennsylvania), Timothy E. O’Connor(University of Northern Iowa), Nikeshan Jeyakumar(Stanford Blood Center), Amy Zhang, Shahbaz A. Malik(University of Nebraska at Omaha), Clayton Jackson, Maryann Stefan(Cleveland Clinic), Katharine Miller(Stanford University), Jozal Moore(University of Rochester Medicine), Ali H Al Darobi, Wendy Stock(University of Chicago)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k